Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | RORB | Q92753 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876162 | 0.88 | MAPT (0.36) | MAPK1LRRK2ACSS2PTGS2 | |
| SCHEMBL875506 | 0.83 | LRRK2 (0.54) | LRRK2 | |
| SCHEMBL876696 | 0.81 | LRRK2 (0.42) | LRRK2 | |
| SCHEMBL874917 | 0.80 | MAPK1 (0.35) | MAPK1LRRK2ROCK2ACSS2 | |
| SCHEMBL883624 | 0.79 | LRRK2 (0.40) | ADORA2AADORA1LRRK2PDE10ACYP1A1 | |
| SCHEMBL13834208 | 0.78 | LRRK2 (0.58) | MAPK1LRRK2 | |
| SCHEMBL16965771 | 0.77 | MAPK1 (0.39) | ADORA2AMAPK1ACSS2PDE10A | |
| SCHEMBL875386 | 0.77 | MAPK1 (0.37) | MAPK1ACSS2 | |
| SCHEMBL875083 | 0.76 | LRRK2 (0.47) | MAPK1LRRK2 | |
| SCHEMBL17084231 | 0.74 | MAPK1 (0.37) | MAPK1ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| EP-2619201-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | ADORA2A 2217/4885ADORA1 2350/4885MAPK1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.